SG11201909709SA - Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin - Google Patents
Stable formulations of fibronectin based scaffold domain proteins that bind to myostatinInfo
- Publication number
- SG11201909709SA SG11201909709SA SG11201909709SA SG11201909709SA SG 11201909709S A SG11201909709S A SG 11201909709SA SG 11201909709S A SG11201909709S A SG 11201909709SA SG 11201909709S A SG11201909709S A SG 11201909709SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- bind
- pct
- rule
- myostatin
- Prior art date
Links
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 title abstract 3
- 108010056852 Myostatin Proteins 0.000 title abstract 3
- 102100037362 Fibronectin Human genes 0.000 title abstract 2
- 108010067306 Fibronectins Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010028289 Muscle atrophy Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 201000000585 muscular atrophy Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762500649P | 2017-05-03 | 2017-05-03 | |
| PCT/US2018/030851 WO2018204617A1 (en) | 2017-05-03 | 2018-05-03 | Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909709SA true SG11201909709SA (en) | 2019-11-28 |
Family
ID=62223280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909709S SG11201909709SA (en) | 2017-05-03 | 2018-05-03 | Stable formulations of fibronectin based scaffold domain proteins that bind to myostatin |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200129595A1 (es) |
| EP (1) | EP3618809A1 (es) |
| JP (2) | JP7157082B2 (es) |
| KR (1) | KR20200003076A (es) |
| CN (1) | CN110621302A (es) |
| AU (1) | AU2018261154B2 (es) |
| CA (1) | CA3062797A1 (es) |
| IL (2) | IL270233B2 (es) |
| MX (1) | MX2019012506A (es) |
| SG (1) | SG11201909709SA (es) |
| TW (1) | TW201842929A (es) |
| WO (1) | WO2018204617A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8933199B2 (en) | 2012-09-13 | 2015-01-13 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
| TW201842929A (zh) | 2017-05-03 | 2018-12-16 | 美商必治妥美雅史谷比公司 | 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
| KR100236393B1 (ko) * | 1996-02-02 | 1999-12-15 | 나까니시 히로유끼 | 사람성장호르몬을 함유하는 의약제제 |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| WO2001072829A2 (en) | 2000-03-31 | 2001-10-04 | Institut Pasteur | Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| AU2001277867B2 (en) | 2000-07-11 | 2006-12-07 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| US6818613B2 (en) * | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
| US20030191187A1 (en) * | 2002-04-01 | 2003-10-09 | Lee Fang Yu | Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| CA2856436A1 (en) | 2005-12-06 | 2007-06-14 | Amgen Inc. | Uses of myostatin antagonists |
| US20100322930A1 (en) | 2007-12-27 | 2010-12-23 | Frank Kolbinger | Fibronectin-based binding molecules and their use |
| CN102007145A (zh) * | 2008-02-14 | 2011-04-06 | 百时美施贵宝公司 | 基于结合egfr的工程化蛋白质的靶向治疗剂 |
| EP2383292A1 (en) | 2008-05-02 | 2011-11-02 | Novartis AG | Improved fibronectin-based binding molecules and uses thereof |
| JP2011520961A (ja) * | 2008-05-22 | 2011-07-21 | ブリストル−マイヤーズ スクイブ カンパニー | 多価フィブロネクチンをベースとする足場ドメインタンパク質 |
| WO2011051466A1 (en) * | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
| EA201270713A1 (ru) | 2010-02-18 | 2013-01-30 | Бристол-Майерс Сквибб Компани | Белки на основе фибронектина с каркасными доменами, которые связывают ил-23 |
| WO2011124718A1 (en) | 2010-04-09 | 2011-10-13 | Novozymes A/S | Albumin derivatives and variants |
| ES2573108T3 (es) * | 2010-05-26 | 2016-06-06 | Bristol-Myers Squibb Company | Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada |
| US20130225496A1 (en) | 2010-11-01 | 2013-08-29 | Novozymes Biopharma Dk A/S | Albumin Variants |
| JP2015524411A (ja) * | 2012-07-18 | 2015-08-24 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | エポキシケトン系プロテアソーム阻害剤のリポソーム組成物 |
| US8933199B2 (en) | 2012-09-13 | 2015-01-13 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
| BR112017021688A2 (pt) * | 2015-04-17 | 2018-08-14 | Bristol-Myers Squibb Company | composições compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo |
| TW201842929A (zh) | 2017-05-03 | 2018-12-16 | 美商必治妥美雅史谷比公司 | 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物 |
-
2018
- 2018-05-02 TW TW107114893A patent/TW201842929A/zh unknown
- 2018-05-03 AU AU2018261154A patent/AU2018261154B2/en active Active
- 2018-05-03 CN CN201880029635.0A patent/CN110621302A/zh active Pending
- 2018-05-03 IL IL270233A patent/IL270233B2/en unknown
- 2018-05-03 WO PCT/US2018/030851 patent/WO2018204617A1/en unknown
- 2018-05-03 SG SG11201909709S patent/SG11201909709SA/en unknown
- 2018-05-03 MX MX2019012506A patent/MX2019012506A/es unknown
- 2018-05-03 JP JP2019560087A patent/JP7157082B2/ja active Active
- 2018-05-03 EP EP18726649.9A patent/EP3618809A1/en active Pending
- 2018-05-03 US US16/607,688 patent/US20200129595A1/en active Pending
- 2018-05-03 CA CA3062797A patent/CA3062797A1/en active Pending
- 2018-05-03 IL IL305625A patent/IL305625A/en unknown
- 2018-05-03 KR KR1020197035212A patent/KR20200003076A/ko active IP Right Grant
-
2022
- 2022-10-06 JP JP2022161758A patent/JP7442595B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018204617A8 (en) | 2019-01-03 |
| IL270233A (es) | 2019-12-31 |
| JP2023011601A (ja) | 2023-01-24 |
| WO2018204617A1 (en) | 2018-11-08 |
| IL270233B2 (en) | 2024-02-01 |
| JP2020518603A (ja) | 2020-06-25 |
| JP7157082B2 (ja) | 2022-10-19 |
| AU2018261154B2 (en) | 2024-05-02 |
| KR20200003076A (ko) | 2020-01-08 |
| IL305625A (en) | 2023-11-01 |
| CA3062797A1 (en) | 2018-11-08 |
| AU2018261154A1 (en) | 2019-11-07 |
| CN110621302A (zh) | 2019-12-27 |
| MX2019012506A (es) | 2019-12-19 |
| TW201842929A (zh) | 2018-12-16 |
| IL270233B1 (en) | 2023-10-01 |
| US20200129595A1 (en) | 2020-04-30 |
| JP7442595B2 (ja) | 2024-03-04 |
| EP3618809A1 (en) | 2020-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201906412SA (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| SG11201811151PA (en) | Extracellular vesicle comprising a fusion protein having fc binding capacity | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201906947SA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201811184UA (en) | Lag -3 binding members | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201900634VA (en) | Chimeric antigen receptor | |
| SG11201408261UA (en) | Syringe | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same |